LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
19 hedge funds and large institutions have $11.2M invested in LAVA Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
3.05% less ownership
Funds ownership: 29.17% → 26.12% (-3.1%)
10% less funds holding
Funds holding: 21 → 19 (-2)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
58% less capital invested
Capital invested by funds: $26.6M → $11.2M (-$15.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Bruce & Co
Chicago,
Illinois
|
+$1.6M |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$149K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$89.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$78.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$2.08M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$833K |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$719K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$530K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$142K |
LVTX Hedge Fund Activity: Q1 2023 in Review
19 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q1 2023, worth a combined $11.2M — down 58% from $26.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LVTX and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Bruce & Co, adding an estimated $1.6M. The largest seller was Redmile Group, cutting an estimated $2.08M.
- 19 institutional investors held LAVA Therapeutics (LVTX) as of Q1 2023, down from 21 in Q4 2022.
- Funds reported $11.2M of LAVA Therapeutics stock for Q1 2023, down 58% quarter-over-quarter.
- 2 funds opened new LAVA Therapeutics positions in Q1 2023 and 4 closed out, a net change of -2 holders.
- The largest LAVA Therapeutics buyer in Q1 2023 was Bruce & Co, an estimated $1.6M added.
- The largest LAVA Therapeutics seller in Q1 2023 was Redmile Group, an estimated $2.08M sold.
Based on aggregated 13F filings for Q1 2023.